
A recent study from the ECLS-SHOCK trial and a comprehensive meta-analysis, presented at ESC Congress 2023, challenges the routine application of Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) for myocardial infarction (MI)-related cardiogenic shock. Contrary to prior trends, the data suggests that VA-ECMO does not significantly enhance survival rates in these patients. Stay updated for more insights into this critical development.
Like
Save
Share